CF
UTHR icon

Cantor Fitzgerald’s United Therapeutics UTHR Stock Holding History

Cantor Fitzgerald’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,000
Closed -$1.15M – 542
2025
Q2 		$1.15M Buy
+4,000
New +$1.2M 0.02% 145

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Cantor Fitzgerald's UTHR Position: Q1 2023 in Review

Cantor Fitzgerald sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 26,170 shares — an estimated $7.28M sold.

Cantor Fitzgerald first reported a position in UTHR in Q2 2022 and held it in 2 quarters. The position peaked at $8.13M in Q2 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Cantor Fitzgerald reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 26,170 United Therapeutics shares in Q1 2023, an estimated $7.28M.
  • Cantor Fitzgerald first reported a position in United Therapeutics in Q2 2022 and held it in 2 quarters.
  • Cantor Fitzgerald's United Therapeutics position peaked at $8.13M in Q2 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Cantor Fitzgerald's 13F filing for Q1 2023, filed 15 May 2023.